Alan D Friedman Selected Research

CCAAT-Enhancer-Binding Protein-alpha

5/2009	NF-kappa B p50 regulates C/EBP alpha expression and inflammatory cytokine-induced neutrophil production.
11/2007	C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment.
6/2006	C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation.
10/2005	CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
7/2002	Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.
6/2002	Induction of granulocytic differentiation by 2 pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan D Friedman Research Topics

Disease

9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2017 - 06/2002
7	Neoplasms (Cancer) 01/2021 - 10/2005
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 05/2016
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2004 - 09/2002
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2020
2	Leukemia 09/2002 - 04/2002
1	Glioblastoma (Glioblastoma Multiforme) 01/2020
1	Carcinoma (Carcinomatosis) 01/2020
1	Fibrosarcoma 01/2020
1	Wilms Tumor (Wilm's Tumor) 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020
1	Pancreatic Ductal Carcinoma 01/2020
1	Glioma (Gliomas) 10/2018
1	Retinoblastoma (Glioblastoma, Retinal) 08/2016
1	Inflammation (Inflammations) 05/2009
1	Central Nervous System Diseases (CNS Diseases) 05/2008
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2008
1	Acute Erythroblastic Leukemia (Erythroleukemia) 06/2006

Drug/Important Bio-Agent (IBA)

6	CCAAT-Enhancer-Binding Protein-alphaIBA 05/2009 - 06/2002
4	Oncogene Proteins (Oncogene Protein)IBA 01/2015 - 09/2002
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 11/2017
3	NF-kappa B (NF-kB)IBA 01/2020 - 10/2005
3	Core Binding Factors (Core-Binding Factor)IBA 12/2002 - 04/2002
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2004
2	Myosin Heavy Chains (Myosin Heavy Chain)IBA 12/2002 - 04/2002
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2021
1	MethyltransferasesIBA 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2020
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2020
1	LuciferasesIBA 01/2020
1	CytokinesIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	Muramidase (Lysozyme)IBA 10/2018
1	Granzymes (Granzyme)IBA 10/2018
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA 01/2018
1	Bortezomib (Velcade)FDA Link 05/2016
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 06/2006
1	fms-Like Tyrosine Kinase 3IBA 03/2004
1	Granulocyte Colony-Stimulating Factor Receptors (G-CSF Receptor)IBA 01/2004
1	Protein Isoforms (Isoforms)IBA 01/2004
1	Myosins (Myosin)IBA 12/2002
1	Core Binding Factor beta SubunitIBA 04/2002

Therapy/Procedure

9	Therapeutics 01/2021 - 12/2002
2	Drug Therapy (Chemotherapy) 01/2020 - 08/2016
1	Highly Active Antiretroviral Therapy (HAART) 05/2008
1	Radiotherapy 05/2008